Pharm Methods, 2023; 14(2): 01-02
A multifaceted peer reviewed journal in the field of Pharm Analysis and Pharmaceutics
www.phmethods.net | www.journalonweb.com/phm

Short Communication

Accelerating Polymorph Screening in Drug Development

Gesieung Li*
Department of Pharmacy, Technical University of Denmark, Silkeborg, Denmark

Received: *15.05.2023, Manuscript No. PHMETHODS-23-108322;* ***Editor assigned:*** *17.05.2023, PreQC No. PHMETHODS-23-108322 (PQ);* ***Reviewed:*** *01.06.2023, QC No. PHMETHODS-23-108322;* ***Revised:*** *08.06.2023, Manuscript No. PHMETHODS-23-108322;* ***Published:*** *15.06.2023, DOI: 10.35248/2229-4708.23.14.248*

Correspondence:
Gesieung Li
Department of Pharmacy, Technical University of Denmark, Silkeborg, Denmark,
E-Mail GesieungLi@gmail.com

DESCRIPTION

In the field of pharmaceuticals, drug polymorphs have gained significant attention due to their potential impact on drug development, formulation, and performance [1-3]. A polymorph is a specific crystal structure that a drug substance can adopt, and different polymorphs of the same drug can exhibit distinct physicochemical properties. Recent advances in understanding and controlling drug polymorphs have opened up new opportunities to improve drug solubility, bioavailability, stability, and overall therapeutic efficacy. In this article, we will explore the significance of drug polymorphs, recent advancements in their characterization, and the implications they hold for the pharmaceutical industry. The existence of different polymorphs of a drug can significantly influence its properties and behavior. Polymorphism arises from the ability of drug molecules to form multiple crystal structures with varying arrangements and packing motifs. These differences can affect important pharmaceutical attributes, such as solubility, dissolution rate, hygroscopicity, melting point, and mechanical properties. As a result, different polymorphs of a drug may display distinct pharmacokinetics and pharmacodynamics, impacting its therapeutic performance in the body. The discovery and control of drug polymorphs are crucial for the pharmaceutical industry as it directly impacts drug development and formulation processes. The selection of an appropriate polymorph during drug development ensures the desired bioavailability, efficacy, and stability of the drug product. Moreover, the understanding of polymorphs can aid in patent strategies, as the discovery of a new polymorph may lead to the extension of a drug's patent life. Advances in analytical techniques have significantly contributed to the characterization and understanding of drug polymorphs. X-ray crystallography remains a fundamental technique for determining the three-dimensional atomic and molecular structure of drug crystals [4]. It provides precise information about the arrangement of atoms within the crystal lattice, allowing the identification and differentiation of polymorphs. Solid-state Nuclear Magnetic Resonance (NMR) spectroscopy has emerged as a powerful tool for investigating the local environment and molecular interactions within solid drug samples. It enables the identification of different polymorphic forms and offers insights into their dynamic behaviour. Powder X-ray Diffraction (PXRD) is a non-destructive technique used to analyze the crystalline structure of drugs in their solid-state. It is highly valuable for identifying different polymorphs and monitoring changes in the crystal form during drug development and formulation processes. Raman spectroscopy provides information about the vibrational modes of molecules and is effective in identifying and characterizing different polymorphs, even in complex formulations [5]. Computational methods, such as molecular modeling and simulations, have become increasingly important for predicting and understanding the stability and properties of various drug polymorphs. These methods aid in the screening of potential polymorphs and contribute to a more efficient drug development process. Polymorph selection can significantly influence the dissolution rate and solubility of a drug. The identification of a polymorph with improved solubility can lead to higher bioavailability and potentially lower dosages for patients. Polymorphic forms can display different stabilities under various environmental conditions. Understanding the stability of different polymorphs is crucial in determining appropriate storage conditions and shelf-life of the drug product. The discovery of new polymorphs can provide pharmaceutical companies with opportunities to extend patent exclusivity, as new polymorphs may be considered as novel drug entities. The choice of polymorph can influence the physical properties of the drug substance, which, in turn, affects formulation design. Polymorph control allows formulators to optimize drug delivery systems, such as tablets, capsules, and parenteral formulations. Polymorphism can be a key element in intellectual property protection strategies. By patenting specific polymorphs, pharmaceutical companies can safeguard their investment in drug development.

CONCLUSION

Recent advances in the study of drug polymorphs have revolutionized the pharmaceutical industry, providing valuable insights into drug development, formulation, and intellectual property protection. The ability to identify, control, and exploit different polymorphs has a profound impact on drug performance, stability, and bioavailability. Advanced analytical techniques, such as X-ray crystallography, solid-state NMR spectroscopy, and computational modeling, have played a pivotal role in understanding the behavior and properties of different polymorphs. As researchers continue to explore the complexities of drug polymorphism, the pharmaceutical industry is poised to leverage this knowledge to develop more effective and stable drug products. The ongoing efforts in polymorph screening, selection, and characterization hold the potential to

optimize drug formulations, enhance patient outcomes, and drive innovation in the field of pharmaceutical sciences.

REFERENCES

1. ALemaitre F, Grégoire M, Monchaud C, Bouchet S, Saint-Salvi B, Polard E, et, al. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for COVID-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT). Therapies. 2022;77(5):509-521.
2. Douglass EF, Allaway RJ, Szalai B, Wang W, Tian T, Fernández-Torras A, et, al. A community challenge for a pancancer drug mechanism of action inference from perturbational profile data. Cell Rep. 2022;3(1).
3. Bai JP, Wang J, Zhang Y, Wang L, Jiang X. Quantitative systems pharmacology for rare disease drug development. J Pharm Sci. 2023.
4. Takesue Y, Hanai Y, Oda K, Hamada Y, Ueda T, Mayumi T, et, al. Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-asian and asian adult patients: Consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring. Clinical Therapeutics. 2022.
5. Moallef S, Dale L, Homayra F, Zonneveld C, Milloy MJ, Nosyk B, et, al. Suboptimal nonmedical qualities of primary care linked with care avoidance among people who use drugs in a Canadian setting amid an integrated health care reform. Journal of Substance Abuse Treatment. 2022;139:108784.